VIEW ONLINE
2019 Integrated Report

ABOUT ASPEN

Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets.

With an acknowledged presence of more than two decades in the pharmaceutical sector, we improve the health of patients in more than 150 countries through our high quality, affordable and effective healthcare solutions. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products.

SENS ANNOUNCEMENTS

INVESTOR CALENDAR

2 December 2019
J.P. Morgan Cazenove’s South Africa Opportunities Conference
Attendee: Luresha Chetty – Investor Relations and Corporate Affairs Executive

5 December 2019
Annual General Meeting

5 March 2020
Interim results announcement for the six months ended 31 December 2019

6 March 2020
Interim results presentation in Cape Town

30 June 2020
Financial year end

LATEST RESULTS

Aspen 2019 Integrated Report

Aspen 2019 Annual Financial Statements

Aspen 2019 Corporate Brochure

Aspen 2019 Fact Sheet

Aspen Year End Results for the year ended 30 June 2019

Aspen Year End Results short form announcement

Aspen Year End Results presentation

Regional
Overviews

DEVELOPED EUROPE

SUB-SAHARAN AFRICA

AUSTRALASIA

LATIN AMERICA

DEVELOPING EUROPE & CIS

China

Japan

Other Asia

Middle East and North Africa

USA & Canada

DEVELOPED EUROPE

Sterile Focus Brands are the leading contributor to the region. The region holds key manufacturing sites which form the base of our strategic growth plans. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key countries
France,
Germany,
Italy,
The Netherlands,
United Kingdom
Number of products launched:
Nil
(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
USD38 million


3 – 5 years
Nil

SUB-SAHARAN AFRICA

The SSA business provides a diverse basket of branded, generic, OTC and consumer health products which are supplied to both the private and public sectors primarily in South Africa. Our Regional Brands have strong brand equity in our home market and we continue to be the leading pharmaceutical company in the South African private sector. Our presence outside of South Africa is mainly in Namibia, Botswana, Tanzania, Kenya, Nigeria, Ghana and Uganda.

Key countries
Botswana, Kenya, Namibia, South Africa, Tanzania
Number of products launched:
22
(2018: 9)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
USD553 million


3 – 5 years
USD232 million

 

Australasia

We supply a diversified portfolio of branded prescription, OTC and consumer health products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semi-solids.

Key countries
Australia,
New Zealand

Number of products launched:
4
(2018: 3)#

#The number of product launches has been restated to take into account discontinued operations.

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
USD85 million


3 – 5 years
USD17 million

Latin America

We have an established history of more than 10 years in Latin America. Mexico and Brazil account for almost 80% of the revenue generated in the region. Our expanded regional coverage gives us a presence Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina. Our comprehensive product range encompasses in branded prescription and OTC products.

Key countries
Brazil, Chile, Colombia,
Ecuador, Mexico

Number of products launched:
8
(2018: 6)#

#The number of product launches has been restated to take into account discontinued operations.

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
USD426 million


3 – 5 years
USD493 million

Developing Europe & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio, followed by the Anaesthetics portfolio which is anticipated to become a significant contributor in this region.

Key countries
The Czech Republic, Poland, Romania, Russia, Slovakia
Number of products launched:
Nil
(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
Nil


3 – 5 years
Nil

China

Aspen China has delivered double-digit revenue growth year-on-year since it was established in FY2017. Our portfolio is led by our Thrombosis and Anaesthetics Brands and also comprises some smaller global brands. Our product portfolio is well placed to deliver value to Chinese patients given our focus on high quality, stable supply and affordable medicines with strong brand equity.

Number of products launched:

Nil
(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
Nil


3 – 5 years
USD16 million

Japan

Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Products launched in 2018

4
(2018: 9)#

#The number of product launches has been restated to take into account discontinued operations.

 

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
Nil


3 – 5 years
Nil

Other Asia

Other Asia comprises all Asian territories excluding China and Japan. Anaesthetics make up 50% of revenue in these countries, followed by several products in the Regional Brands category. We have active trading subsidiaries in the Philippines, Taiwan, Hong Kong and Malaysia. Our manufacturing facility in India is our primary new product development site.

Key countries and territories
Hong Kong, the Philippines, Singapore, Taiwan

Number of products launched:
2
(2018: 3)#

#The number of product launches has been restated to take into account discontinued operations.

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
Nil


3 – 5 years
USD1 million

Middle East and North Africa

We supply globally branded pharmaceutical products as well as local brands into multiple territories within Middle East and North Africa (“MENA”). Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2019 financial year.

Key countries
Algeria, Egypt, Morocco, Saudi Arabia, United Arab Emirates

Number of products launched:
7
(2018: 5)#

#The number of product launches has been restated to take into account discontinued operations.

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:
0 – 2 years
USD107 million


3 – 5 years
USD145 million

USA & Canada

Aspen Canada was founded in 2014 to support our products distributed in this region. The development of our complex API capabilities into niche FDF offerings represents an opportunity for future product launches in the United States. Our satellite API facility in Sioux City supports the Oss site in supplying APIs worldwide.

Key countries
Canada
USA

Number of products launched:
Nil
(2018: 1)#

#The number of product launches has been restated to take into account discontinued operations.

In-market sales value of pipeline as at 3 June 2019 anticipated to be launched in:
0 – 2 years
USD1 103 million


3 – 5 years
USD1 210 million